Pictet Asset Management Holding SA Boosts Stock Holdings in Sanofi $SNY

Pictet Asset Management Holding SA raised its stake in Sanofi (NASDAQ:SNY – Free Report) by 3.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 624,011 shares of the company’s stock after acquiring an additional 19,358 shares during the period. Pictet Asset Management Holding SA’s holdings in Sanofi were worth $30,171,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Sanctuary Advisors LLC grew its position in shares of Sanofi by 2.9% during the fourth quarter. Sanctuary Advisors LLC now owns 117,630 shares of the company’s stock valued at $5,700,000 after purchasing an additional 3,335 shares in the last quarter. Golden State Equity Partners lifted its position in shares of Sanofi by 19.8% in the fourth quarter. Golden State Equity Partners now owns 5,687 shares of the company’s stock worth $276,000 after buying an additional 940 shares in the last quarter. Concurrent Investment Advisors LLC lifted its position in shares of Sanofi by 61.5% in the fourth quarter. Concurrent Investment Advisors LLC now owns 20,408 shares of the company’s stock worth $989,000 after buying an additional 7,774 shares in the last quarter. ProVise Management Group LLC boosted its stake in Sanofi by 6.6% during the fourth quarter. ProVise Management Group LLC now owns 224,422 shares of the company’s stock valued at $10,875,000 after buying an additional 13,891 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its stake in Sanofi by 13.7% during the fourth quarter. Geneos Wealth Management Inc. now owns 15,993 shares of the company’s stock valued at $775,000 after buying an additional 1,924 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Bank of America downgraded Sanofi from a “buy” rating to a “neutral” rating in a research note on Thursday, February 12th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Sanofi in a report on Friday, January 16th. Citigroup reaffirmed a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Barclays lowered shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, January 6th. Finally, Argus raised shares of Sanofi to a “strong-buy” rating in a research note on Monday. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $54.00.

Check Out Our Latest Analysis on SNY

Sanofi Stock Performance

NASDAQ SNY opened at $46.03 on Thursday. The business’s 50 day moving average price is $46.40 and its 200-day moving average price is $47.92. Sanofi has a fifty-two week low of $43.32 and a fifty-two week high of $55.73. The company has a market cap of $112.27 billion, a P/E ratio of 12.86, a P/E/G ratio of 1.14 and a beta of 0.42. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01.

Sanofi Increases Dividend

The company also recently declared an annual dividend, which will be paid on Wednesday, June 3rd. Investors of record on Monday, May 4th will be issued a dividend of $2.4225 per share. This represents a yield of 502.0%. The ex-dividend date is Monday, May 4th. This is a positive change from Sanofi’s previous annual dividend of $2.04. Sanofi’s payout ratio is currently 49.16%.

Sanofi Company Profile

(Free Report)

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

Further Reading

• Five stocks we like better than Sanofi

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).